NSF Minority Faculty Development Workshop Alexis Bakos, PhD, MPH, RN,C Chief, Diversity Training...
-
Upload
isabel-strickland -
Category
Documents
-
view
215 -
download
2
Transcript of NSF Minority Faculty Development Workshop Alexis Bakos, PhD, MPH, RN,C Chief, Diversity Training...
NSF Minority Faculty Development Workshop
Alexis Bakos, PhD, MPH, RN,CAlexis Bakos, PhD, MPH, RN,CChief, Diversity Training BranchChief, Diversity Training Branch
Center to Reduce Cancer Health Disparities, Center to Reduce Cancer Health Disparities, NCINCI
OPPORTUNITIES FOR TRAINEES TO OPPORTUNITIES FOR TRAINEES TO PROMOTE DIVERSITYPROMOTE DIVERSITY
March 23, 2010March 23, 2010
HSHS UndergradUndergrad PredoctoralPredoctoral PostdoctoralPostdoctoral Junior InvestigatorJunior Investigator
R25T: Prevention and Control Clinical Oncology
Training Grants: K12
TransitionCareer: K22
NRSA Fellowships: F31 and T32 S
Career AwardsK01 K08 K23
Cancer Center Grant: P30
SPORE: P50 TranslationalCancer Center: P30 MD/POR
R
0
1
R03
R21
Continuing Umbrella of Research Continuing Umbrella of Research ExperiencesExperiences
DiversitySupplements
Supplements to the CURE:
Career Development
Supplement Eligibility
Eligible Individuals Ethnic and/or racial minorities Socio-economically disadvantaged groups First generation college graduates Individuals with disabilities Must be US Citizen or permanent residentEligible Grants■ NCI grants
Receipt of Supplement
Applications by the NCI
■ Application Receipt: Two Cycles ■ October 1 through December 1 ■ March 1 through May 1
■ Notice of Award: Office of Grants Administration
Research Supplements to Promote Diversity in Health
Related Research
■ Available for every career level e.g. High School through Junior faculty
■ Provides up to five years of support
■ * For T32, R25T, and K12 the supplement is awarded after slots are filled
http://grants.nih.gov/grants/guide/pa-files/PA-08-190-html
Supplements to Promote Reentry into Biomedical and Behavioral Research
Careers Available for individuals who want to
reestablish active research careers Provides up to 3 years of support Period of career interruption is 1 to 8 years Candidate must have a doctoral degree Support for salary, fringe benefits, supplies
and travel
http://grants.nih.gov/grants/guide/pa-files/PA-08-191.html
Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer
Research
Mechanism: R21 (PAR-09-162) Purpose: To increase the diversity of
the research workforce by supporting investigators from diverse populations in the area of basic cancer research.
Direct Cost: $275,000 for 2 years Receipt Dates: Nov 23rd and June 23rd
Exploratory/Developmental Grants Program for Basic Cancer Research in
Cancer Health Disparities
Mechanism: R21 (PAR-09-160) Purpose: To promote basic cancer
research expertise in cancer health disparities
Direct Cost: $275,000 for 2 yrs Receipt Date: Nov 23rd and June 23rd
Basic Cancer Research in Cancer Health Disparities
Mechanism: U01 (PAR-09-161) Cooperative agreement FOA to conduct
basic research into the causes and treatment of cancer health disparities New methodologies Secondary data analyses Innovative mechanistic studies
$250,000/yr for up to 5 yrs Receipt Date: Nov 23rd and June 23rd
Office of Technology & Industrial Relations (OTIR)Innovative Technology Development for Cancer Research Mechanism R21 (RFA-CA-10-005) Feasibility studies on early stage
development (i.e., at their conceptual stage where feasibility has not been established) of cancer-relevant technologies in the area of CA biology, prevention, diagnosis, treatment, epidemiology & cancer health disparities
Up to $500,000 over 3 yr period Receipt Date: May 27 and Sept. 30, 2010
Office of Technology & Industrial Relations (OTIR)Application & Early Stage Development of Emerging Technology in Cancer Research Mechanism: R21 (RFA-CA-10-003) Feasibility studies on emerging cancer-
relevant technologies (i.e., has passed the initial development stage but hasn’t been evaluated within the context of its intended use) in the area of CA biology, prevention, diagnosis, treatment, epidemiology & cancer health disparities
Up to $275,000 direct costs over 2 yrs Receipt Date: May 27 and Sept. 30, 2010
Office of Technology & Industrial Relations (OTIR)Innovative & Early-Stage Development of Emerging Technologies in Biospecimen Science Mechanism R21 (RFA-CA-10-001) Early stage studies that develop
technologies capable of interrogating &/or maximizing the quality & utility of biospecimens
Up to $275,000 direct costs over 2 yrs Receipt Date: May 27 and Sept. 30,
2010
■ Creates a pipeline of diverse cancer investigators
■ Investigators become mentors
Manuel Penichet, M.D., Ph.D. Dr. Penichet and trainees
Example:Manuel Penichet, UCLARecipient of:*Diversity Supplement*K award *R01s
• For Supplements• Peter Ogunbiyi:
For R21 & U01 Funding Opportunities Anil Wali: [email protected]
For OTIR Funding Opportunities LeeAnn Bailey: [email protected]
Main Office: 301-496-7344
DTB Contacts